{
    "2020-03-12": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Form 8.3 - ABBVIE INC",
                "features": {
                    "keywords": [
                        "Form 8.3",
                        "ABBVIE INC"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "AbbVie Stock Falls 7%",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Stock",
                        "Falls",
                        "7%"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "AbbVie Receives European Commission Approval of VENCLYXTOÂ® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "European Commission",
                        "Approval",
                        "VENCLYXTO",
                        "Chronic Lymphocytic Leukemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "&quot;Massive&quot; RD is Paying Off for AbbVie",
                "features": {
                    "keywords": [
                        "Massive",
                        "RD",
                        "Paying Off",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}